Physician profile
Jeffrey Clement
NPI 1164420576
$7,441.85
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,248 · 2020: $901 · 2021: $1,987 · 2022: $1,393 · 2023: $802 · 2024: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $675 · Education: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $674.93 |
| Education | $238.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,151.17 | 2019-2023 | Lokelma, Farxiga |
| Vifor Pharma, INC. | $942.97 | 2019-2023 | Veltassa, Korsuva |
| Amgen INC. | $644.12 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $627.79 | 2019-2023 | Jynarque |
| Akebia Therapeutics INC | $461.52 | 2019-2022 | |
| Opko Pharmaceuticals, LLC | $402.27 | 2019-2024 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $397.24 | 2021-2022 | |
| Horizon Therapeutics Plc | $353.94 | 2019-2021 | |
| Fresenius USA Marketing, INC. | $351.41 | 2019-2023 | Velphoro |
| Janssen Pharmaceuticals, INC | $334.27 | 2019-2021 | |
| Glaxosmithkline, LLC. | $283.90 | 2021-2024 | Benlysta, Jesduvroq |
| Alexion Pharmaceuticals, INC. | $246.42 | 2019-2023 | Ultomiris |
| Aurinia Pharma U.S., INC. | $244.73 | 2021-2022 | |
| Daiichi Sankyo INC. | $210.83 | 2020-2021 | |
| Calliditas Therapeutics US INC. | $139.18 | 2022-2023 | Tarpeyo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.62 | 2020 | |
| Travere Therapeutics, INC. | $98.07 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $89.49 | 2022 | |
| Mallinckrodt Hospital Products INC. | $55.42 | 2020-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $41.57 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.45 | 2020-2021 | |
| Strongbridge US INC. | $37.59 | 2019-2020 | |
| Cmp Pharma, INC. | $27.07 | 2022 | |
| Arbor Pharmaceuticals, INC. | $25.88 | 2020 | |
| Alnylam Pharmaceuticals INC. | $25.69 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $25.30 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $23.22 | 2019 | |
| Mallinckrodt Enterprises LLC | $21.76 | 2019 | |
| Shire North American Group INC | $14.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Clement listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.